FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3037202317> ?p ?o ?g. }

• W3037202317 endingPage "786" @default.
• W3037202317 startingPage "777" @default.
• W3037202317 abstract "Abstract Simultaneously targeting other pathways could increase the activity of PD-1 blockade in lymphoid malignancies not sensitive to single-agent blockade. We explored the safety and efficacy of combined PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory (R/R) lymphoid malignancies. This phase 1b trial enrolled adult patients with R/R classical Hodgkin lymphoma (cHL), non-Hodgkin lymphoma (NHL), or multiple myeloma (MM). Patients received nivolumab plus ipilimumab (nivo/ipi) or lirilumab (nivo/liri) until complete response (CR), progression, or unacceptable toxicity. The primary endpoint was safety and tolerability, while secondary endpoints included overall (ORR) and CR rates (CRR), progression-free and overall survival. Sixty-five patients were treated with nivo/ipi, and 72 with nivo/liri. Twenty-nine percent of patients experienced grade 3–4 treatment-related adverse events with nivo/ipi, and 15% with nivo/liri. In cHL, ORR was 74% for nivo/ipi and 76% for nivo/liri, CRRs were 23% and 24%, respectively. In B-NHL and T-NHL, ORR range was 9–22% and CRR was 0–6%. No patient with MM had an objective response. While both combinations were active in cHL, the toxicity of nivo/ipi was higher than expected from nivolumab alone. These data suggest no meaningful improvement in the efficacy of the combinations over single-agent nivolumab in the diseases studied." @default.
• W3037202317 created "2020-07-02" @default.
• W3037202317 creator A5022339242 @default.
• W3037202317 creator A5032617342 @default.
• W3037202317 creator A5034547254 @default.
• W3037202317 creator A5059729547 @default.
• W3037202317 creator A5066129729 @default.
• W3037202317 creator A5067245939 @default.
• W3037202317 creator A5071407925 @default.
• W3037202317 creator A5081564280 @default.
• W3037202317 date "2020-06-29" @default.
• W3037202317 modified "2023-10-14" @default.
• W3037202317 title "A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies" @default.
• W3037202317 cites W1986354050 @default.
• W3037202317 cites W2003734726 @default.
• W3037202317 cites W2032166347 @default.
• W3037202317 cites W2047353087 @default.
• W3037202317 cites W2073989522 @default.
• W3037202317 cites W2096850086 @default.
• W3037202317 cites W2097995306 @default.
• W3037202317 cites W2108395794 @default.
• W3037202317 cites W2112601576 @default.
• W3037202317 cites W2123023182 @default.
• W3037202317 cites W2125616358 @default.
• W3037202317 cites W2128758225 @default.
• W3037202317 cites W2133201432 @default.
• W3037202317 cites W2147068163 @default.
• W3037202317 cites W2147240268 @default.
• W3037202317 cites W2164433065 @default.
• W3037202317 cites W2166662937 @default.
• W3037202317 cites W2412725897 @default.
• W3037202317 cites W2473498748 @default.
• W3037202317 cites W2504623699 @default.
• W3037202317 cites W2516271598 @default.
• W3037202317 cites W2560704457 @default.
• W3037202317 cites W2591946624 @default.
• W3037202317 cites W2609973112 @default.
• W3037202317 cites W2784868445 @default.
• W3037202317 cites W2786224778 @default.
• W3037202317 cites W2794872274 @default.
• W3037202317 cites W2890056446 @default.
• W3037202317 cites W2909334052 @default.
• W3037202317 doi "https://doi.org/10.1038/s41375-020-0939-1" @default.
• W3037202317 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7932914" @default.
• W3037202317 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32601377" @default.
• W3037202317 hasPublicationYear "2020" @default.
• W3037202317 type Work @default.
• W3037202317 sameAs 3037202317 @default.
• W3037202317 citedByCount "65" @default.
• W3037202317 countsByYear W30372023172020 @default.
• W3037202317 countsByYear W30372023172021 @default.
• W3037202317 countsByYear W30372023172022 @default.
• W3037202317 countsByYear W30372023172023 @default.
• W3037202317 crossrefType "journal-article" @default.
• W3037202317 hasAuthorship W3037202317A5022339242 @default.
• W3037202317 hasAuthorship W3037202317A5032617342 @default.
• W3037202317 hasAuthorship W3037202317A5034547254 @default.
• W3037202317 hasAuthorship W3037202317A5059729547 @default.
• W3037202317 hasAuthorship W3037202317A5066129729 @default.
• W3037202317 hasAuthorship W3037202317A5067245939 @default.
• W3037202317 hasAuthorship W3037202317A5071407925 @default.
• W3037202317 hasAuthorship W3037202317A5081564280 @default.
• W3037202317 hasBestOaLocation W30372023171 @default.
• W3037202317 hasConcept C121608353 @default.
• W3037202317 hasConcept C126322002 @default.
• W3037202317 hasConcept C142424586 @default.
• W3037202317 hasConcept C143998085 @default.
• W3037202317 hasConcept C170493617 @default.
• W3037202317 hasConcept C197934379 @default.
• W3037202317 hasConcept C203092338 @default.
• W3037202317 hasConcept C2777701055 @default.
• W3037202317 hasConcept C2778375690 @default.
• W3037202317 hasConcept C2778468042 @default.
• W3037202317 hasConcept C2779338263 @default.
• W3037202317 hasConcept C2780030458 @default.
• W3037202317 hasConcept C2781433595 @default.
• W3037202317 hasConcept C535046627 @default.
• W3037202317 hasConcept C71924100 @default.
• W3037202317 hasConcept C86803240 @default.
• W3037202317 hasConcept C87355193 @default.
• W3037202317 hasConceptScore W3037202317C121608353 @default.
• W3037202317 hasConceptScore W3037202317C126322002 @default.
• W3037202317 hasConceptScore W3037202317C142424586 @default.
• W3037202317 hasConceptScore W3037202317C143998085 @default.
• W3037202317 hasConceptScore W3037202317C170493617 @default.
• W3037202317 hasConceptScore W3037202317C197934379 @default.
• W3037202317 hasConceptScore W3037202317C203092338 @default.
• W3037202317 hasConceptScore W3037202317C2777701055 @default.
• W3037202317 hasConceptScore W3037202317C2778375690 @default.
• W3037202317 hasConceptScore W3037202317C2778468042 @default.
• W3037202317 hasConceptScore W3037202317C2779338263 @default.
• W3037202317 hasConceptScore W3037202317C2780030458 @default.
• W3037202317 hasConceptScore W3037202317C2781433595 @default.
• W3037202317 hasConceptScore W3037202317C535046627 @default.
• W3037202317 hasConceptScore W3037202317C71924100 @default.
• W3037202317 hasConceptScore W3037202317C86803240 @default.
• W3037202317 hasConceptScore W3037202317C87355193 @default.
• W3037202317 hasFunder F4320307115 @default.

• next